"Fantastic roster of talent" and recommended for being "very modern, forward-thinking and providing sound commercial advice" as well as offering instructing solicitors "a very broad skill set in the soft IP space."Chambers & Partners 2017

"8 New Square is undoubtedly one of the leading sets for trade mark and copyright cases within the media and entertainment sphere, so much so that stablemates here frequently find themselves pitted against each other in major cases."Chambers & Partners (Media & Entertainment) 2014

Regeneron & Bayer v Genentech [2012] EWHC 657

Regeneron and Bayer issued revocation and non-infringement proceedings against Genentech in relation to its patent for the use of VEGF antagonists to treat non-neoplastic diseases characterised by excessive angiogenesis. The patent was alleged to be anticipated or obvious over a paper which disclosed an antagonist to VEGF and which stated that the antagonist may have therapeutic potential. The patent was also alleged to be insufficient on numerous bases, including that the patent did not enable the invention across the scope of all the claimed diseases. The Judge rejected the novelty attack because the publication did not clearly and unambiguously teach the claimed therapeutic effect. The patent was held to be inventive over the prior art because the publication expressed no “concluded view” as to which (if any) of the available growth factors could be used for therapeutic purposes. The patent was held to teach a principle of general application and the attacks based on insufficiency also failed. The Judge held that the Claimants’ new treatment for age-related macular degeneration of the eye infringed the patent.

We use cookies to make this site as useful as possible. They are small text files we put in your browser to track usage of our site but they don't tell us who you are. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. If you would like to change your preferences you may do so by following the instructions here